Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
05 8월 2023 - 2:43AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
commercial-stage biopharmaceutical company, today announced the
closing of its public offering of 5,930,000 units, with each unit
consisting of one share of common stock (or pre-funded warrant in
lieu thereof) and one warrant to purchase one share of common
stock. Each unit was sold at a public offering price of $1.35. The
common warrants are immediately exercisable at a price of $1.35 per
share and expire five years from the date of issuance. The shares
of common stock (or pre-funded warrants in lieu thereof) and
accompanying common warrants were only purchasable together in this
offering, but were issued separately and immediately separable upon
issuance.
Gross proceeds, before deducting placement agent fees and other
offering expenses, were approximately $8.0 million.
Maxim Group LLC is acting as sole placement agent in connection
with this offering.
The securities described above were offered pursuant to a
registration statement on Form S-1, as amended (File No.
333-273233) (the “Registration Statement”), previously filed with
and subsequently declared effective by the Securities and Exchange
Commission (the “SEC”) on August 1, 2023. The offering was made
only by means of a prospectus which is a part of the Registration
Statement. A copy of the final prospectus relating to this offering
has been filed with the SEC and may be obtained from Maxim Group
LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212)
895-3745.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a commercial stage
neuro-biotech company primarily focused on developing and
commercializing products for the treatment of opioid overdose and
substance use disorders. Adamis’ commercial products approved by
the FDA include ZIMHI® (naloxone) Injection for the treatment of
opioid overdose, and SYMJEPI® (epinephrine) Injection for use in
the emergency treatment of acute allergic reactions, including
anaphylaxis. Following its recent merger transaction with DMK
Pharmaceuticals, the Company is also developing novel therapies for
opioid use disorder (OUD) and other important neuro-based
conditions where patients are currently underserved. The Company’s
lead clinical stage product candidate, DPI-125, is being studied as
a potential novel treatment for OUD. Adamis also plans to develop
the compound for the treatment of moderate to severe pain. The
Company’s other development stage product candidates include
DPI-221 for bladder control problems and DPI-289 for severe end
stage Parkinson’s disease. For additional information about Adamis
Pharmaceuticals, please visit our website and follow us on Twitter
and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements about our
expectations, beliefs and intentions as well as statements relating
to the public offering, including, without limitation, as to the
consummation of the offering described above and the Company’s
ability to satisfy the closing conditions related to the offering,
the expected proceeds from the offering, the timing of the closing
of the offering, and our products and product candidates. Any
statements in this press release about our future expectations,
plans and prospects, including statements regarding our strategy,
future operations, prospects, plans and objectives, and other
statements containing the words "believes," "anticipates," "plans,"
"expects," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. These statements are only predictions and
involve known and unknown risks, uncertainties, and other factors,
which may cause Adamis’ actual results to be materially different
from the results anticipated by such forward-looking statements.
Adamis cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or
occur. Accordingly, you should not rely upon forward-looking
statements as predictions of future events. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
satisfaction of closing conditions and the closing of the offering;
our cash flow, cash burn, expenses, obligations and liabilities;
the future success of any of our product development programs;
future trends regarding opioid use disorder, alcohol use disorder
or other substance use disorders; our ability to raise required
capital to continue as a going concern; the outcomes of any
litigation, regulatory proceedings, claims or investigations that
we are or may become subject to; our ability to maintain the
continued listing of our common stock on the Nasdaq Capital Market
and regain compliance with Nasdaq’s marketplace rules; and other
risks and uncertainties described in the Company's annual report
filed with the Securities and Exchange Commission (“SEC”) on Form
10-K for the year ended December 31, 2022, and in the Company's
subsequent filings with the SEC, all of which are available free of
charge on the SEC’s website at http://www.sec.gov. The Company
provides links to third-party websites only as a courtesy to
readers and disclaims any responsibility for the thoroughness,
accuracy or timeliness of information at third-party websites. If
we do not obtain sufficient funds to continue operations or satisfy
our liabilities and obligations, our cash resources will be
depleted and we could be required to materially reduce or suspend
operations, which would likely have a material adverse effect on
our business and stock price, or we could be required to seek
bankruptcy protection or other alternatives that could result in
our stockholders losing some or all of their investment in us. Such
forward-looking statements speak only as of the date of this press
release, and Adamis disclaims any intent or obligation to update
these forward-looking statements or links to third party websites
contained herein, whether as a result of new information, to
reflect events or changed circumstances or otherwise, after the
date of such statements, except as may be required by law.
Contact:Adamis Investor RelationsRobert UhlManaging DirectorICR
Westwicke619.228.5886
Adamis Pharmaceuticals (NASDAQ:ADMP)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024